Celgene’s Oral Mongersen Could Be Game-Changer In Crohn’s Disease
This article was originally published in The Pink Sheet Daily
New England Journal of Medicine editorial says that if Phase II results for Celgene’s oral antisense candidate mongersen (GED-0301) are confirmed, the drug’s durable effect “would be unprecedented and would represent a first step toward curing the disease.”
You may also be interested in...
Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the first day of the 2015 J.P. Morgan Healthcare Conference in San Francisco.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.